2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Cardiotoxicity
7
Lymphoma, Non-Hodgkin
5
Breast Neoplasms
5
Neoplasms
4
Lymphoma
4
Prostatic Neoplasms
3
Myelodysplastic Syndromes
3
Lung Neoplasms
3
Leukemia
3
Hematologic Neoplasms
3
Heart Failure
3
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Small Cell Lung Carcinoma
2
Rectal Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Multiple Myeloma
2
Lymphoma, B-Cell
2
Leukemia, Myeloid, Acute
2
Dyslipidemias
2
Colonic Neoplasms
2
Cardiovascular Diseases
2
Carcinoma in Situ
2
Burkitt Lymphoma
2
Vulvar Neoplasms
1
Vulvar Diseases
1
Ventricular Dysfunction, Left
1
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Urinary Bladder Neoplasms
1
Interventions
Brentuximab Vedotin
21
Cyclophosphamide
20
fludarabine
16
Rituximab
13
Lenalidomide
13
Dexamethasone
12
fludarabine phosphate
10
Melphalan
10
Busulfan
10
Mycophenolic Acid
9
pirtobrutinib
7
dacetuzumab
7
Whole-Body Irradiation
7
Tacrolimus
7
Bortezomib
7
Doxorubicin
6
Azacitidine
6
ruxolitinib
5
Vincristine
5
Prednisone
5
Imatinib Mesylate
5
Bone Marrow Transplantation
5
ponatinib
4
pomalidomide
4
Mesna
4
Granulocyte Colony-Stimulating Factor
4
Etoposide
4
Blood Specimen Collection
4
Bendamustine Hydrochloride
4
venetoclax
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hematologic Diseases
×
Electrocardiography
×
Clear all
NCT07387354
2026-03-16
MDS
Thomas Jefferson University
Phase 1/2
Not yet recruiting
25 enrolled